plantmad
biofarm
viral
vaccin
earliest
product
technolog
plant
molecular
farm
remain
brightest
prospect
success
field
proof
principl
efficaci
exist
mani
candid
viral
veterinari
vaccin
use
plantmad
viral
antigen
monoclon
antibodi
therapi
anim
even
human
viral
diseas
also
well
establish
review
explor
promin
recent
advanc
biofarm
viral
vaccin
therapi
includ
recent
use
zmapp
ebolaviru
infect
explor
possibl
futur
applic
technolog
recent
candid
viral
vaccin
produc
plant
hepat
b
viru
hbv
vaccin
one
blockbust
vaccin
success
stori
modern
time
sinc
identif
viru
took
less
scienc
molecular
farm
use
plant
plant
cell
cultur
produc
highvalu
recombin
protein
start
product
via
transgen
tobacco
sunflow
chimaer
human
growth
hormon
monoclon
antibodi
transgen
tobacco
human
serum
albumin
transgen
tobacco
cell
cultur
follow
onward
express
first
candid
viru
vaccin
antigen
hepat
b
viru
hbv
surfac
antigen
hbsag
epitop
footandmouth
diseas
viru
fmdv
express
surfac
particl
recombin
cowpea
mosaic
viru
cpmv
see
tabl
initi
prevail
idea
use
plantproduc
vaccin
deliv
plant
materi
edibl
vaccinessometh
alreadi
question
earli
howev
concept
larg
fallen
favour
realis
administr
vaccin
human
requir
standardis
dose
measur
qualiti
control
necess
purif
formul
larg
accept
year
sinc
mani
protein
express
candid
vaccin
therapeut
mani
differ
plantbas
express
system
tri
grow
trend
toward
transient
express
system
base
infiltr
whole
plant
recombin
agrobacterium
tumefacien
agroinfiltr
use
deconstruct
plant
viral
vector
review
viru
vaccin
larg
excit
part
field
almost
begin
diseas
agent
rang
hepat
b
c
foot
mouth
diseas
virus
human
papillomaviru
human
rotaviru
ovin
bluetongu
rabbit
haemorrhag
diseas
virus
mention
aspect
histori
cover
recent
particular
viruslik
particl
base
vaccin
includ
rotavirus
norwalk
viru
human
papillomavirus
hepat
b
viru
discuss
detail
except
new
materi
cover
review
cover
relev
recent
histori
virusspecif
candid
vaccin
virusspecif
therapeut
antibodi
made
plant
view
provid
object
exampl
success
approach
especi
dual
humananim
use
one
health
exampl
http
wwwonehealthinitiativecom
order
help
inform
futur
work
first
express
hbv
surfac
antigen
plant
human
clinic
trial
plantproduc
hbsag
first
product
hbsag
transgen
banana
use
rtmvmediat
transient
express
mgkg
hbsag
use
rbeydvmedi
transient
express
produc
mgkg
hbc
ag
tabletis
lyophilis
transgen
lettuc
contain
hbsag
vlp
oral
immunogen
mice
hepat
c
viru
use
rtmv
express
epitop
protein
ctb
fusion
express
chimaer
plant
viru
coat
protein
molecul
contain
cp
vlp
oral
immunogen
via
feed
lettuc
leav
rabbit
mix
respons
mice
rodlik
epitop
chimaer
vlp
coexpress
whole
calnexin
calreticulin
increas
accumul
plant
influenza
virus
evid
highyield
express
haemagglutininderiv
vlp
via
transient
express
million
vaccin
dose
rapid
fire
mileston
medicago
inc
darpa
blue
angel
programm
human
clinic
trial
plantmad
vaccin
candid
haonli
vlp
produc
outbreak
viru
phase
trial
hpai
haderiv
plantmad
product
test
plantmad
engin
solubl
trimer
ha
mice
adjuv
monomer
ha
sio
bi
cyclic
dimer
guanosin
monophosph
cdigmp
emerg
respons
influenza
vaccin
candid
made
south
africa
conjug
plantmad
ha
tmv
particl
success
test
mice
elicit
neutralis
ab
elastinlik
polypeptid
fuse
stabilis
solubl
trimerform
ha
present
epitop
surfac
rtmv
virion
elicit
protect
immun
homolog
heterolog
challeng
mice
papillomavirus
proof
efficaci
plantmad
cottontail
rabbit
rabbit
oral
papillomaviru
vaccin
high
yield
vlp
via
agroinfiltrationmedi
transient
express
via
transplastom
express
transplastom
express
capsomereform
fuse
escherichia
coli
ltb
builtin
adjuv
success
express
bovin
papillomaviru
vlp
plant
coexpress
e
coli
ltb
oral
immunis
elicit
increas
intestin
mucos
iga
respons
highyield
plant
transient
express
chimaer
vlp
proof
increas
breadth
immun
respons
rpvx
cp
fusion
epitop
yield
well
elicit
hightitr
protein
sera
mice
plant
product
scaleup
protect
efficaci
mous
model
therapeut
fusion
protein
vaccin
plant
express
ctermin
string
tcell
epitop
viabl
prophylactictherapeut
vaccin
candid
product
proof
efficaci
mice
solubl
therapeut
vaccin
transplastom
chlamydomona
reinhardtii
proof
yield
increas
efficaci
mous
tumour
model
shuffl
protein
fuse
peptid
human
immunodefici
viru
capsid
protein
express
success
transgen
tobacco
transgen
maiz
product
platform
oral
vaccin
deliveri
test
use
siv
major
surfac
glycoprotein
transientlyexpress
molecul
fuse
ctb
elicit
antimembran
proxim
region
mpr
antibodi
mice
gagderiv
antigen
express
transient
transgen
ctlinduc
booster
immunogen
highyield
transplastom
express
gag
vlp
phase
clinic
trial
antihiv
mab
produc
transgen
tobacco
year
subunit
vaccin
get
market
howev
form
nm
subvir
particl
purifi
serum
human
carrier
hbv
although
highli
effect
expens
produc
limit
supplyto
say
noth
everpres
risk
associ
blood
product
isol
hbv
carrier
may
carri
number
yet
undetect
virus
triumph
modern
molecular
biolog
therefor
similar
viruslik
particl
vlp
vaccin
deriv
express
hbv
small
surfac
antigen
shbsag
develop
initi
still
expens
us
three
intramuscular
dose
necessarypric
come
significantli
point
countri
routin
immunis
infant
part
extend
programm
immunis
epi
recombin
vaccin
highli
effect
safe
help
set
standard
later
introduct
recombin
vlpbase
human
papillomaviru
hpv
vaccin
howev
still
space
improv
hbv
vaccin
term
cost
good
specif
antigen
content
increas
desir
worldwid
needlefre
vaccin
deliveri
exampl
would
requir
cheaper
product
larger
amount
antigen
oral
deliveri
current
product
modal
would
abl
meet
problem
nonrespons
certain
group
peopl
current
vaccin
also
necessit
develop
third
gener
product
contain
middl
mhbsag
andor
larg
lhbsag
surfac
antigen
contain
strongli
immunogen
andor
domain
howev
vaccin
expens
less
readili
avail
accordingli
plant
product
hbsagbas
hbv
vaccin
gone
year
varieti
product
made
preclin
test
oral
deliveri
transgen
potatodeliv
product
almost
long
preclin
trial
orallydeliv
product
human
clinic
trial
oral
deliveri
hbsag
transgen
plant
materi
prove
particularli
effect
howev
immunogen
gener
low
effect
led
gener
curtail
transgenicplanta
vaccin
effort
interest
regard
despit
concept
vaccin
via
banana
hype
popular
press
sinc
eg
http
gminfectiousdiseas
hbsag
first
express
transgen
banana
fruit
india
albeit
rel
low
yield
recent
review
propos
combin
approach
parenter
vaccin
purifi
plantproduc
hbsag
follow
oral
boost
less
well
purifi
antigen
tablet
capsul
preliminari
studi
mice
use
lyophilis
hbsag
vlpproduc
transgen
lettuc
convert
tablet
appear
add
weight
propos
highest
plant
yield
convent
small
hbsag
achiev
via
use
deconstruct
tobacco
mosaic
virusbas
cdna
magnicon
vector
icon
genet
hall
germani
around
mgkg
wet
weight
nicotiana
benthamiana
recombin
protein
fulllength
form
disulphidelink
dimer
display
conformationallydetermin
antigen
determin
assembl
correctli
vlp
tabl
highlight
histor
recent
activ
viru
vaccin
biofarm
continu
rtmvbase
express
gag
vlpbase
deconstruct
multiantigen
incorpor
gp
mper
region
first
success
publish
express
hiv
env
plant
p
envelop
protein
express
high
yield
transient
express
hiv
ha
fusion
molecul
result
vlp
format
veterinari
one
health
vaccin
product
plant
proof
efficaci
sheep
intact
vlp
bluetongu
viru
rabi
viru
vaccin
produc
plant
shown
protect
includ
oral
administr
crimeancongo
haemorrhag
fever
viru
gc
gn
glycoprotein
immunogen
mice
via
oral
parenter
administr
plantproduc
rift
valley
fever
viru
gn
n
protein
immunogen
feed
mice
transgen
arabidopsi
express
via
rbeydv
success
immunogen
trial
mice
ebola
mab
hc
antivir
therapeut
antibodi
product
success
efficaci
test
antirabi
viru
mab
made
transgen
tobacco
highyield
product
via
rbeydv
antiebolaviru
zair
west
nile
viru
mab
transient
express
via
rtmv
success
preand
postexposur
efficaci
trial
macaqu
antiebola
mab
cocktail
success
efficaci
trial
macaqu
zmapp
therapeut
mab
cocktail
legend
rtmv
recombin
tobacco
mosaic
viru
includ
icon
vector
rbeydv
recombin
bean
yellow
dwarf
mastreviru
interestingli
vacuummedi
agroinfiltr
whole
plant
led
better
product
determin
presenc
determin
plant
express
hbv
antigen
standard
hbsag
attempt
recent
year
number
group
arizona
biodesign
institut
group
pioneer
much
biofarm
hbv
vaccin
show
form
hbsag
could
use
via
transient
agroinfiltrationmedi
express
use
fusion
partner
ntermin
fusion
amino
acid
toler
without
alter
particleform
abil
major
antigen
properti
follow
demonstr
hbsag
middl
protein
protein
highli
immunogen
amino
acid
region
fuse
nterminu
proteincould
success
produc
plant
elicit
stronger
humor
immun
respons
protein
inject
mice
group
use
magnicon
vector
express
gkg
wet
weight
plant
vlpform
highli
immunogen
hbcag
core
antigen
hbc
consider
potenti
therapeut
vaccin
display
vehicl
peptid
includ
hbv
pre
region
subsequ
paper
biodesign
institut
group
detail
use
ssdna
bean
yellow
dwarf
mastrevirusbas
vector
system
review
produc
mgkg
hbcag
n
benthamiana
safe
say
potenti
product
hbv
vaccin
plant
well
realis
wholli
edibleorallyadminist
vaccin
may
remain
pipedream
level
antigen
product
hbsag
hbcag
achiev
highest
plantproduc
molecul
product
shown
antigen
appropri
highli
immunogen
million
peopl
worldwid
chronic
infect
hepat
c
viru
hcv
around
peopl
die
annual
hcvrelat
liver
diseas
signific
proport
infect
clear
infect
natur
major
go
develop
chronic
infectionswith
risk
cirrhosi
liver
within
year
treatment
present
avail
antivir
common
regim
combin
antivir
therapi
interferon
ribavirin
effect
viral
genotyp
newer
drug
becom
avail
promis
sofosbuvir
howev
vaccin
effect
mean
prevent
infect
occur
plant
product
candid
hcv
vaccin
reason
long
histori
given
viru
describ
interest
first
product
intend
therapeut
vaccin
nemchinov
colleagu
describ
use
tobacco
mosaic
viru
tmv
deriv
vector
n
benthamiana
express
synthet
hypervari
region
deriv
peptid
call
potenti
neutralis
epitop
hcv
deriv
envelop
protein
fuse
ctermin
b
subunit
cholera
toxin
ctb
plantderiv
react
immun
sera
individu
infect
four
major
genotyp
hcv
mice
immunis
intranas
crude
plant
extract
produc
antibodi
specif
bound
hcv
vlp
follow
success
report
plant
express
chimaer
plant
viru
coat
protein
molecul
contain
epitop
includ
use
cucumb
mosaic
viru
cmv
cp
immunoreact
sera
chronic
infect
patient
recombin
cp
lead
use
purifi
elicit
vivo
respons
rabbit
vitro
cellular
respons
measur
interferon
gamma
product
lymphocyt
human
patient
subsequ
group
show
purifi
particl
stabl
simul
gastric
intestin
condit
could
elicit
humor
immun
respons
rabbit
fed
infect
lettuc
plant
epitop
also
express
fusion
product
alfalfa
mosaic
viru
amv
cp
via
transfect
plant
transgen
amv
rna
recombin
cpencod
react
monoclon
antibodi
immun
sera
individu
infect
hcv
anoth
approach
use
epitop
plantproduc
ctermin
fusion
papaya
mosaic
viru
pmv
cp
led
format
flexibl
rodlik
vlp
activ
internalis
bonemarrowderiv
antigen
present
cell
apc
mice
inject
twice
vlp
exhibit
humor
respons
last
day
cp
epitop
product
suggest
mix
respons
anoth
interest
recent
develop
file
uspto
patent
applic
plant
product
whole
protein
appar
particularli
success
misfold
patent
cover
agroinfect
n
benthamiana
cell
express
recombin
protein
one
molecular
chaperon
calnexin
calreticulin
lead
improv
yield
recombin
protein
add
appear
success
express
albeit
low
level
hcv
protein
plant
appear
though
plant
product
candid
therapeut
vaccin
hcv
quit
well
cover
howev
prophylact
vaccin
space
far
less
well
investig
hope
chang
optimis
plant
product
fulllength
protein
detail
human
season
influenza
current
mainli
caus
virus
two
distinct
genera
influenzaviru
three
influenza
virus
two
lineag
influenza
b
viru
yamagata
victoria
annual
attack
rate
global
estim
adult
children
million
case
sever
ill
death
convent
chicken
eggbas
inactiv
wholeviru
split
vaccin
technolog
product
capac
billion
dose
trival
vaccin
product
level
million
dose
albeit
sixmonth
leadin
period
everi
year
manifestli
obvious
capabl
deal
pandem
potenti
vaccin
suppli
would
fall
sever
billion
dose
short
amount
need
provid
protect
global
popul
worth
note
report
issu
three
year
pandemicand
prophet
predict
vaccin
shortag
overli
long
interv
identif
pandem
agent
avail
vaccin
report
went
say
vaccin
develop
certainti
pandem
viru
emerg
current
global
capac
manufactur
influenza
vaccin
limit
two
dose
may
need
pandem
vaccin
absenc
preexist
immun
could
delay
time
achiev
protect
add
oper
challeng
deliveri
high
antigen
content
may
requir
would
limit
total
number
dose
made
avail
current
eggbas
technolog
inactiv
vaccin
emphasi
target
popul
vaccin
could
potenti
entir
global
popul
six
billion
would
requir
comprehens
resourc
support
oper
logist
demand
mani
countri
respect
last
point
worth
note
northern
hemispher
influenza
vaccin
product
capac
rate
million
dose
actual
product
million
dose
southern
hemispher
capac
million
dose
product
million
thu
provis
pandem
vaccin
global
south
would
fact
grave
lack
current
technolog
indebt
one
refere
review
observ
import
egg
liter
place
one
basketor
vaccin
put
egg
perhap
fortun
influenza
vaccin
major
success
stori
plantexpress
antigen
larg
due
two
major
factor
first
haemagglutinin
ha
protein
main
determin
neutralis
essenti
compon
vaccin
second
appear
well
express
plant
fold
properli
perhap
signific
factor
plant
express
ha
howev
fact
express
alon
suffici
effici
format
high
yield
highli
immunogen
vlp
bud
plant
cell
outer
membran
especi
relev
influenza
vaccin
develop
light
fact
hacontain
vlp
produc
insect
cell
elicit
broader
crossneutralis
immun
respons
whole
virion
inactiv
influenza
viru
recombin
ha
properti
exploit
number
group
work
report
detail
elsewher
accordingli
review
limit
recent
develop
specif
interest
pandem
season
human
vaccin
develop
plantbas
technolog
lend
well
orphan
nich
vaccin
effect
infinit
scalabl
product
also
well
suit
manufactur
rapid
respons
vaccin
direct
pandem
influenza
bioterror
agent
reason
us
defens
advanc
research
project
agenc
darpa
launch
acceler
manufactur
pharmaceut
amp
programm
includ
investig
suitabl
plant
manufactur
platform
purpos
respons
swine
flu
viru
pandem
initi
blue
angel
effort
acceler
integr
effort
deliv
effect
intervent
pandem
influenza
part
involv
use
us
million
fund
challeng
four
compani
demonstr
capabl
use
plant
produc
million
dose
influenza
vaccin
month
fraunhof
usa
center
molecular
biotechnolog
delawar
kentucki
bioprocess
owensboro
project
greenvax
consortium
partner
texa
univers
system
gcon
texa
medicago
usa
north
carolina
juli
medicago
inc
produc
part
rapid
fire
mileston
million
dose
vlpbase
influenza
vaccin
candid
one
month
phase
current
good
manufactur
practic
cgmp
latest
develop
contend
challeng
includ
preclin
human
clinic
trial
number
habas
product
first
medicago
ha
vlp
vaccin
candid
constitut
first
ever
report
administr
plantmad
vlp
vaccin
human
preclin
work
report
paper
two
low
dose
alumadjuv
plantmad
vlp
ferret
prevent
patholog
reduc
viral
load
follow
heterotyp
clade
viru
lethal
challeng
interestingli
protect
occur
despit
fact
hai
titr
avietnam
challeng
viru
detect
challeng
ferret
prompt
comment
correl
protect
influenza
viru
infect
fulli
understood
vlp
probabl
stimul
innat
immun
respons
seen
convent
vaccin
human
trial
ha
vlp
perform
healthi
adult
year
age
receiv
dose
day
apart
mg
alumadjuv
vlp
vaccin
placebo
alum
immunogen
evalu
use
haemagglutinationinhibit
hai
singl
radial
hemolysi
srh
microneutralis
mn
assay
result
three
assay
highli
correl
clear
doserespons
measur
immunogen
almost
dose
group
mount
detect
mn
respons
indic
promis
immunogen
word
data
particularli
encourag
light
fact
tradit
eggbas
split
vaccin
show
modest
immunogen
human
dose
high
mg
without
alum
adjuv
one
particularli
encourag
aspect
studi
test
plantspecif
glycan
respons
studi
group
one
purport
potenti
hazard
plantmad
vaccin
possibl
might
exacerb
preexist
allergi
plant
nglycan
even
elicit
respons
de
novo
clear
negat
potenti
vaccin
studi
found
ige
plantspecif
glycan
subject
signific
statist
differ
increas
igg
plant
glycan
placebo
vaccin
group
may
import
influenza
vaccin
made
differ
express
system
shown
evid
glycosyl
recombin
acalifornia
ha
made
insect
cell
plant
differ
high
mannos
type
glycan
plantexpress
complex
type
glycoform
insectexpress
ha
evid
glycosyl
ha
may
affect
immunogen
includ
fact
antibodi
titr
higher
insect
cellderiv
ha
neutralis
hai
titr
much
higher
cho
mammalian
cellproduc
ha
although
seem
problem
plantproduc
ha
vlp
illustr
speed
scalabl
transient
express
n
benthamiana
emerg
respons
novel
influenza
viru
outbreak
shown
recent
medicago
inc
produc
gram
cgmpgrade
plantmad
vaccin
haonli
vlp
respons
outbreak
human
sever
influenza
viru
china
first
vaccin
lot
avail
day
compani
access
ha
gene
cdna
sequenc
littl
one
dose
vlp
vaccin
administ
without
gla
glucopyranosyl
lipid
adjuv
elicit
high
antibodi
titr
mice
account
phase
trial
haderiv
hpai
haderiv
product
publish
research
fraunhof
center
molecular
biotechnolog
delawar
usa
http
www
fraunhoferorgmolecularbiotechnolog
follow
proof
could
use
tmvbase
transient
express
system
produc
protein
recombin
ha
sequenc
includ
kdel
er
retent
affin
purif
sequenc
ctermini
purifi
use
detergentcontain
buffer
nisepharos
hydrophob
interact
anion
exchang
chromatographi
column
scale
kg
n
benthamiana
biomass
cgmp
mous
immunogen
studi
demonstr
intramuscular
im
inject
ha
ha
protein
adsorb
alhydrogel
adjuv
elicit
serum
hai
antibodi
respons
titr
least
vaccin
mice
signific
enhanc
immunogen
consequ
dosespar
afford
use
adjuv
rabbit
two
im
dose
ha
plu
alhydrogel
elicit
hai
titr
anim
two
dose
ha
requir
titr
rabbit
result
ferret
similar
lower
respons
ha
conclus
studi
antigen
safe
immunogen
suit
human
trial
contrast
preclin
result
howev
test
ha
vaccin
human
volunt
show
enhanc
immunogen
alhydrogel
dose
alhydrogel
adjuv
dose
without
alhydrogel
administ
twodos
regimen
three
week
apart
highest
respons
unadjuv
group
ha
vaccin
antigen
test
sera
deriv
human
volunt
vaccin
convent
adjuv
vaccin
order
assess
vaccin
potenti
recogn
strongli
serum
antibodi
antibodysecret
cell
vaccin
addit
good
correl
result
obtain
use
plantmad
antigen
convent
vaccin
antigen
elispot
intracellular
cytokin
stain
assay
conclus
candid
ha
good
vaccin
potenti
need
good
adjuv
use
clinic
trial
done
recent
firstinhuman
phase
studi
ha
given
twice
dose
level
without
alhydrogel
healthi
adult
year
age
highest
seroconvers
rate
measur
hai
viru
mn
assay
nonadjuv
vaccin
group
second
vaccin
dose
thu
result
two
plantmad
monomer
candid
ha
vaccin
similar
high
dose
requir
obtain
suitabl
respons
andunlik
medicago
trial
obviou
effect
use
alhydrogel
adjuv
also
question
whether
vaccin
antigen
contain
tag
would
licenc
final
product
anoth
product
group
howev
promis
engin
solubl
trimer
ha
heterolog
trimeris
motif
induc
serum
antibodi
activ
hai
assay
well
protect
immun
mice
given
lethal
viru
challeng
may
expect
effect
dose
trimer
ha
much
lower
previous
requir
monomer
ha
describ
explor
enhanc
immunogen
monomer
ha
also
promis
entail
doublyadjuv
antigen
silica
nanoparticl
sio
mucos
adjuv
candid
bi
cyclic
dimer
guanosin
monophosph
cdigmp
mice
vaccin
intratrach
result
system
humor
immun
respons
induct
strong
mucos
immun
respons
antigenprim
tcell
lung
biofarm
often
tout
ideal
vaccin
pharmaceut
product
develop
world
littl
actual
publish
develop
countri
use
technolog
purpos
one
object
exampl
come
lab
south
africa
explor
prospect
make
emerg
respons
pandem
influenza
vaccin
success
make
highyield
candid
subunit
vaccin
via
transient
agroinfiltrationmedi
express
n
benthamiana
fulllength
mgkg
fw
solubl
version
mgkg
fw
aviet
ha
via
human
codonus
optim
ha
gene
show
protein
elicit
usabl
titr
antibodi
mice
chicken
hai
assay
full
length
protein
significantli
better
subsequ
work
show
fulllength
ha
could
extract
semipur
vlp
apoplast
space
unmacer
n
benthamiana
leav
via
buffer
infiltr
gentl
centrifug
cut
leav
roll
strip
h
inderth
ii
hitzeroth
ep
rybicki
unpublish
figur
number
differ
plantproduc
influenza
vaccin
candid
earlier
stage
develop
show
promis
includ
ha
protein
attach
number
differ
partner
molecul
well
candid
univers
vaccin
base
highli
conserv
ion
channel
protein
ectop
domain
chemic
conjug
plantmad
monomer
ha
surfac
tobacco
mosaic
viru
tmv
virion
produc
vaccin
elicit
potent
antibodi
respons
measur
hai
allow
dosespar
mice
singl
im
dose
suffici
protect
mice
test
given
either
alum
alhydrogel
squalen
oilinwat
base
adjuv
addavax
adjuv
tmv
carrier
also
uniqu
har
dendrit
cell
dc
uptak
subsequ
activ
stimul
effect
antigen
present
influenc
qualiti
subsequ
protect
immun
respons
use
tmv
antigen
carrier
allow
repeat
boost
without
loss
immun
activ
partner
antigen
even
antitmv
antibodi
alreadi
present
fact
prior
exposur
fulllength
ha
produc
use
ptraerh
vector
modifi
apoplast
secret
describ
mortim
et
al
particl
elut
gentl
centrifug
leav
vacuum
infiltr
phosphat
buffer
salin
ph
cut
strip
roll
insert
centrifug
tube
tmv
potenti
respons
ha
group
abl
produc
g
monomer
ha
protein
pilot
scale
less
montha
good
advertis
potenti
technolog
emerg
respons
vaccin
capabl
anoth
interest
approach
make
elastinlik
polypeptid
fusion
stabilis
solubl
trimerform
ha
elpyl
ha
product
enhanc
elpyl
molecul
could
easili
purifi
characterist
invers
transit
cycl
techniqu
elicit
neutralis
antibodi
mice
bound
plantproduc
ha
vlp
inactiv
eggproduc
viru
product
influenza
viru
antigen
limit
protein
investig
extent
peptid
ectop
domain
ion
channel
protein
consider
potenti
univers
vaccin
candid
highli
conserv
influenza
virus
insert
peptid
two
differ
locat
human
papillomaviru
type
vlpform
protein
report
use
surfac
display
filament
vlpform
potexviru
cp
albeit
without
preclin
evalu
howev
recent
investig
use
surfac
display
tmv
virion
noteworthi
synthet
peptid
deriv
viru
insert
tmv
cp
residu
well
display
virion
candid
vaccin
elicit
high
antibodi
titr
im
immunis
mice
protect
homolog
challeng
viru
heterolog
challeng
plantmad
influenza
virus
gener
habas
vaccin
particular
seem
product
signific
potenti
still
avenu
exploresuch
express
test
neuraminidas
na
matrix
protein
nucleoprotein
np
play
role
immun
recoveri
influenza
viru
infect
could
constitut
valuabl
addit
plantmad
influenza
vaccin
armouri
human
papillomaviru
hpv
vaccin
base
vlp
made
recombin
express
assembl
major
capsid
protein
latest
blockbust
viral
vaccin
annual
sale
merck
yeastmad
gardasil
gsk
insect
cellmad
cervarix
vlpbase
vaccin
close
higher
us
billion
gardasil
target
two
preval
hpv
found
cervic
cancer
case
well
two
common
genit
wartcaus
virus
hpv
cervarix
contain
hpv
global
impact
target
diseas
develop
worldin
women
develop
countri
account
annual
case
cervic
cancer
case
worldwid
annual
death
cervic
cancer
worldwid
main
market
vaccin
develop
world
larg
due
expens
chang
extent
number
govern
negoti
favour
tender
suppli
hpv
vaccin
epi
programm
remain
problemand
immin
releas
nextgener
product
wider
coveragemixtur
type
hpv
chimaer
vaccin
includ
part
minor
capsid
protein
vaccin
noth
fix
problem
anoth
problem
yet
unaddress
avail
vaccin
therapeut
vaccin
alreadi
infect
highrisk
hpv
sever
genit
wart
neither
gardasil
cervarix
effect
establish
infect
neither
new
wider
coverag
vlpbase
vaccin
elicit
overwhelmingli
humor
antibodi
respons
seen
far
experiment
vaccin
base
highrisk
hpv
oncogen
shown
promis
anim
model
howev
given
burden
cervic
diseas
well
cancer
develop
countri
problem
cost
small
market
size
problem
licenc
vaccin
develop
plantbas
product
human
papillomaviru
vaccin
quit
long
histori
well
review
hpv
vaccin
specif
vlp
briefli
import
earli
landmark
farm
prophylact
papillomaviru
vaccin
proof
transgenicallyexpress
assembl
immunogen
vlp
albeit
low
yield
proof
efficaci
plantmad
cottontail
rabbit
papillomaviru
crpv
vaccin
rabbit
oral
papillomaviru
crpv
peptid
surfacedisplay
rtmv
vaccin
high
yield
vlp
via
agroinfiltrationmedi
transient
express
via
transplastom
chloroplast
express
interest
approach
shown
studi
use
transplastom
plant
express
mutat
form
pentamer
capsom
rather
particl
fuse
escherichia
coli
heatlabil
enterotoxin
subunit
b
ltb
builtin
adjuv
result
protein
accumul
total
solubl
protein
tsp
correct
epitop
biochem
activ
parent
molecul
indic
could
viabl
vaccin
candid
one
investig
look
nongenit
hpv
studi
plant
express
highrisk
cutan
papillomaviru
associ
epidermodysplasia
verruciformi
nonmelanoma
skin
cancer
immunocompromis
peopl
express
protein
form
vlp
planta
albeit
rel
low
yield
ctermin
nuclear
localis
signal
remov
similar
found
contrast
result
remov
lower
yield
third
investig
express
nonhuman
papillomaviru
reason
high
level
protein
mgml
biomass
achiev
transient
agroinfiltrationmedi
express
bovin
papillomaviru
type
protein
form
vlp
albeit
nm
particl
rather
nm
nativ
structur
nevertheless
highli
immunogen
rabbit
document
express
minor
papillomaviru
capsid
protein
laboratori
report
human
codon
optimis
express
level
mgkgwhich
note
time
could
use
protein
present
virion
maximum
ratio
molecul
per
capsomer
given
yield
higher
coexpress
protein
could
result
effici
vlp
format
candid
therapeut
vaccin
base
oncoprotein
investig
detail
first
express
protein
plantstransi
express
n
benthamiana
via
recombin
potato
viru
xderiv
vector
accompani
proof
efficaci
mous
model
protect
tumour
develop
caus
cell
line
accompani
strong
cytotox
tcell
respons
group
went
show
enhanc
express
target
protein
secretori
pathway
possibl
immuneenhanc
properti
n
benthamiana
extract
indic
previou
work
explor
proof
immunomodulatori
activ
human
monocyt
deriv
dendrit
cell
mddc
possibl
respons
concern
use
unmodifi
oncoprotein
vaccin
engin
mutat
abolish
interact
cell
cycl
govern
protein
show
plantproduc
fusion
product
lickm
clostridium
thermocellum
elicit
protect
respons
experiment
scaleup
product
fusion
protein
therapeut
vaccin
achiev
final
yield
mgkg
biomass
protein
puriti
mean
metalion
affin
chromatographi
gel
filtrat
interest
fusion
prophylact
potenti
therapeut
hpv
vaccin
investig
feasibl
produc
chimaer
vlp
fuse
string
cytotox
tlymphocyt
epitop
hpv
protein
transgen
tomato
plant
lycopersicon
esculentum
express
level
low
vlp
form
planta
elicit
neutralis
antibodi
ctl
respons
develop
work
use
chimaer
vlp
made
tomato
plant
detect
specif
antibodi
patient
grade
cervic
intraepitheli
lesion
cin
point
potenti
use
plantmad
product
inexpens
reagent
new
develop
area
mainli
prophylact
vlpbase
vaccin
limit
studi
larg
involv
chimaer
molecul
fusion
partner
howev
one
recent
interest
variant
classic
hpv
vlp
approach
one
coexpress
e
coli
ltb
doubli
transgen
tobacco
n
tabacum
plant
reason
yield
tsp
extract
use
oral
immunis
mice
day
combin
ltb
dramat
increas
intestin
mucos
iga
respons
well
splenic
cell
prolifer
express
cell
spleen
cell
supernat
studi
chimaer
molecul
group
investig
neutralis
antibodi
epitop
deriv
compris
amino
acid
residu
substitut
ctermin
helix
region
amino
acid
follow
evid
effect
term
elicit
wider
spectrum
crossneutralis
antibodi
highrisk
hpv
follow
previou
experi
use
human
codonus
optimis
gene
similarlyoptimis
insert
transient
express
n
benthamiana
via
agroinfiltr
target
import
chloroplast
chimaera
highli
express
yield
gkg
plant
tissu
chimaera
contain
amino
acid
success
candid
assembl
small
vlp
nm
elicit
respons
im
immunis
mice
immun
sera
neutralis
homolog
heterolog
pseudovirion
chimaer
form
distinct
particl
elicit
significantli
weaker
humor
immun
respons
dose
protein
particl
format
contrast
repeat
previou
express
chimaera
insect
cell
loos
aggreg
capsom
form
anoth
investig
potenti
epitop
undertaken
use
fusion
peptid
nterminu
potato
viru
x
coat
protein
pvx
cp
surfac
display
express
via
recombin
pvx
vector
n
benthamiana
express
level
mgkg
biomass
obtain
chimaer
protein
elicit
reactiv
antibodi
sc
inject
tattoo
administr
vaccin
continu
investig
number
approach
yield
promis
result
use
crossov
approach
mix
potenti
prophylact
therapeut
vaccin
group
develop
chimaera
string
tcell
epitop
hpv
fuse
cterminu
worker
immunis
mice
antigen
could
demonstr
persist
igg
antibodi
month
good
neutralis
activ
also
effici
longterm
protect
tumour
growth
induc
tumour
cell
challeng
signific
tumour
reduct
anim
establish
tumour
given
therapeut
vaccin
anoth
use
pvx
cp
fusion
time
protein
mention
previous
shown
nand
ctermin
fusion
pvx
cp
form
long
filament
vlp
express
e
coli
express
n
benthamiana
high
level
latter
appar
form
vlp
anoth
product
modal
investig
form
transplastom
chlamydomona
reinhardtii
wellcharacteris
unicellular
alga
express
alon
flag
fusion
protein
level
tsp
affin
purif
perform
tag
form
mice
vaccin
sc
c
reinhardtii
extract
purifi
protein
mix
quila
adjuv
specif
igg
tcell
prolifer
shown
mice
vaccin
either
inoculum
tumour
protect
shown
challeng
tumour
cell
line
express
author
note
first
success
express
solubl
deriv
plant
previous
protein
express
fusion
product
order
get
usabl
yield
anoth
recent
paper
explor
express
transplastom
tobacco
determin
target
protein
mean
transit
peptid
thylakoid
lumen
chloroplast
inner
compart
differ
redox
potenti
stroma
among
characteristicsincreas
product
howev
author
inactiv
oncogen
potenti
protein
mean
present
valu
illustr
use
yield
enhanc
techniqu
group
recent
explor
potenti
novel
gene
constructa
synthet
shuffl
lost
transform
properti
retain
naturallyoccur
ctl
epitopesfor
express
plant
candid
therapeut
vaccin
gene
previous
success
use
dna
vaccin
mous
tumour
model
elicit
potent
cellular
humor
immun
respons
includ
tumour
protect
regress
fuse
gene
translat
one
encod
peptid
selfassembl
domain
maiz
gammazein
seed
storag
protein
induc
accumul
recombin
protein
protein
bodi
pb
within
endoplasm
reticulum
varieti
eukaryot
express
system
gener
allow
stabilis
recombin
protein
well
enhanc
accumul
far
easier
purif
alon
express
low
level
agroinfiltrationmedi
transient
express
n
benthamiana
highlevel
express
achiev
maximum
gkg
biomass
result
protein
bodi
could
easili
purifi
immun
respons
compar
dna
vaccin
demonstr
mice
specif
humor
well
cellmedi
immun
respons
signific
tumour
regress
vaccin
mice
preexist
tumour
interestingli
simpli
mix
zeraonli
pb
also
enhanc
immun
respons
indic
independ
adjuv
activ
compon
moreov
use
gene
dna
vaccin
also
result
increas
level
mous
splenocyt
compar
mice
inocul
gene
trend
also
observ
granzym
b
elispot
assay
well
chromium
releas
assay
feel
demonstr
proof
efficaci
mous
tumour
model
novel
hpv
therapeut
vaccin
candid
easi
cheap
produc
purifi
develop
vaccin
dna
vaccin
prime
follow
match
protein
boost
might
ideal
order
achiev
enhanc
immunogen
overal
prospect
plant
product
prophylact
therapeut
vaccin
hpv
infect
diseas
appear
bright
goldstandard
vlpbase
vaccin
candid
made
high
yield
via
transient
express
viabl
therapeut
vaccin
candid
efficaci
demonstr
anim
model
type
vaccin
earli
pipelin
research
appear
show
feasibl
make
dualpurpos
vaccin
may
prevent
infect
hasten
recoveri
infect
littl
need
either
reiter
need
vaccin
human
immunodefici
virus
hiv
gener
predomin
particular
also
littl
need
face
plethora
literatur
detail
approach
problem
inher
develop
said
vaccin
could
expect
hiv
vaccin
earli
target
plant
express
studi
varieti
target
inde
capsid
protein
express
success
transgen
tobacco
albeit
low
yield
tsp
long
ago
suitabl
transgen
maiz
product
platform
oral
deliveri
hiv
vaccin
seed
extract
test
use
siv
major
surfac
glycoprotein
novel
molecul
incorpor
ctb
fusion
polymeris
agent
adjuv
produc
via
agroinfiltrationmedi
express
n
benthamiana
shown
produc
mucos
serum
antimembran
proxim
region
mpr
antibodi
mice
mucos
primesystem
boost
immunis
tat
monom
produc
spinach
via
rtmv
potenti
oral
vaccin
epitop
deriv
gag
env
fuse
hbsag
express
vlp
transgen
tomato
fruit
variou
gagderiv
antigen
produc
transgen
tobacco
via
rtmv
n
benthamiana
investig
util
ctlinduc
immunogen
group
nef
produc
n
benthamiana
use
agroinfiltrationmedi
transient
express
system
field
comprehens
review
recent
review
limit
discuss
major
advanc
recent
work
mani
vari
antigen
produc
variou
type
plant
use
varieti
express
system
systemat
investig
antigen
regard
central
mainstream
hiv
vaccin
productionthat
fulllength
gag
envand
clinic
trial
candid
vaccin
product
although
plantproduc
antihiv
mab
gone
phase
trial
success
express
fulllength
pr
gag
precursor
polyprotein
date
done
subtyp
b
gag
transplastom
tobacco
yield
nm
diamet
vlp
mgkg
biomass
close
previou
best
group
vlp
produc
transgen
tobacco
repres
viabl
yield
product
seriou
vaccin
potenti
recent
evid
lack
progress
aid
link
strong
ctl
respons
gag
reinforc
need
vaccin
target
respons
pr
gag
vlp
potent
elicitor
ctl
especi
use
protein
boost
heterolog
prime
primat
model
recent
paper
detail
antigen
express
transgen
either
arabidopsi
thaliana
daucu
carota
show
prime
effect
mice
fed
whole
plant
materi
elicit
humor
immun
respons
detect
serum
igg
intramuscular
purifi
protein
boost
interest
dosedepend
antigen
analys
use
transgen
thaliana
show
low
antigen
dose
superior
high
dose
new
plantmad
hiv
multiantigen
make
use
vlp
consist
gag
deconstruct
form
compris
membran
proxim
extern
transmembran
cytoplasm
domain
combin
proven
qualiti
gag
vlp
selfadjuv
potent
humor
cellular
responseinduc
immunogen
envelop
protein
compris
membran
proxim
extern
region
mper
hiv
import
infect
process
elicit
broadli
neutralis
antihiv
antibodi
gag
gene
extens
deconstruct
term
remov
potenti
methyl
site
cryptic
splice
polyadenyl
site
plant
codonus
optimis
gag
express
constitut
transgen
n
benthamiana
plant
control
camv
promot
level
mgkg
biomass
transgen
plant
infiltr
agrobacterium
transform
deconstruct
magnicon
replic
vector
express
envelop
protein
target
apoplast
mean
barley
alphaamylas
signal
peptid
coexpress
allow
greater
accumul
protein
mgkg
iodixanol
densiti
gradient
centrifug
indic
coexpress
protein
cosedi
denser
fraction
express
alon
similarli
gagonli
fraction
known
contain
vlpsand
inde
nm
diamet
envelop
vlp
seen
extract
situ
plant
leaf
section
could
shown
bud
medium
protoplast
cotransfect
cell
believ
author
exagger
claim
find
provid
impetu
journey
toward
broadli
efficaci
inexpens
subunit
vaccin
given
vaccin
candid
includ
whole
gag
popular
envderiv
target
antigen
express
fulllength
env
even
plant
elus
target
singl
publish
account
plantbas
express
env
despit
highli
success
adjunct
demonstr
rapid
highlevel
transient
product
function
hiv
broadli
neutralis
monoclon
antibodi
env
hiv
envelop
develop
vaccin
research
centr
nih
express
stabl
transgen
n
tabacum
transient
via
agroinfiltr
n
benthamiana
kdeltag
nativ
form
er
retent
secret
consequ
differenti
glycosyl
success
express
mgkg
biomassand
purifi
leaf
homogen
clarif
follow
galanthu
nivali
agglutinin
gna
lectin
column
affin
deae
ion
exchang
chromatographi
expect
erretain
secret
form
differenti
glycosyl
former
contain
omt
glycan
complex
glycan
latter
low
percentag
complextyp
nglycan
low
percentag
complex
glycan
similar
high
mannos
glycan
virionassoci
env
differ
higher
percentag
complex
glycan
env
produc
mammalian
cell
line
plantmad
env
also
bound
mab
produc
either
cho
cell
also
produc
plant
indic
signific
differ
mammalian
cellproduc
env
first
convinc
evid
product
hivvaccinerelev
env
molecul
plant
togeth
evid
gagbas
vlp
includ
env
deriv
previou
work
indic
true
hiv
vlp
could
produc
plant
system
one
envrel
product
modal
plant
could
commerci
interest
hiv
well
virus
human
anim
reveal
patent
file
medicago
inc
detail
use
chimaer
construct
ectodomain
envelop
viru
trimer
surfac
proteinssuch
retrovirus
rhabdovirus
herp
corona
paramyxo
poxand
filovirus
fuse
influenza
viru
ha
protein
transmembran
domain
cytoplasm
tail
order
produc
vlp
similar
haonli
vlp
previous
mention
hiv
env
construct
fusion
variou
portion
con
engin
env
lack
cleavag
site
fusion
peptid
immunodomin
region
cytoplasm
tail
ct
domain
transmembran
tm
ct
domain
portion
either
ha
molecul
word
patent
although
nativ
hiv
env
protein
poorli
accumul
plant
chimer
hiv
env
protein
fuse
transmembran
tm
cytoplasm
tail
ct
domain
influenza
ha
accumul
high
level
bud
hiv
vlp
absenc
core
matrix
protein
plant
could
provid
genuin
novel
sourc
hiv
env
antigen
enhanc
immunogen
especi
use
boost
vaccin
heterolog
primeboost
vaccin
regim
one
excit
success
stori
veterinari
biofarm
recent
year
undoubtedli
proof
efficaci
plantmad
vlpbase
vaccin
bluetongu
viru
btv
muticompon
dsrnacontain
orbiviru
famili
reovirida
project
part
eu
plant
product
vaccin
plaprova
initi
http
wwwplaprovaeu
whose
activ
vlpbase
vaccin
partli
report
bluetongu
diseas
rel
newli
emerg
problem
sheep
goat
northern
europ
almost
certainli
result
climat
chang
affect
distribut
culicoid
midg
transmit
vaccin
seen
essenti
part
diseas
control
howev
unlik
case
endem
area
south
africa
attenu
live
vaccin
use
routin
concern
vaccin
safeti
possibl
emerg
new
strain
viru
genom
reassort
live
vaccin
strain
result
push
develop
recombin
proteinonli
vaccin
establish
recombin
express
btv
protein
insect
anim
cell
cultur
system
result
varieti
structur
form
express
alon
produc
subcorelik
particl
sclp
togeth
produc
corelik
particl
clp
express
plu
produc
authent
vlp
build
evid
vlp
protect
sheep
challeng
live
viru
plaprova
group
investig
whether
possibl
use
plantproduc
antigen
gene
construct
base
netherland
strain
sequenc
gene
nicotiana
codonus
optimis
gene
clone
express
peaqht
express
vector
contain
cowpea
mosaic
viru
cpmv
deriv
ht
hypertran
translat
enhanc
sequenc
interestingli
infiltr
n
benthamiana
plant
either
alon
produc
necrot
symptom
combin
protein
necrosi
observ
simpl
screen
clarifi
extract
densiti
gradient
ultracentrifug
show
express
alon
four
togeth
result
virion
protein
cosedi
highmw
aggreg
problem
stoichiometri
result
rel
overexpress
overaccumul
sclp
address
use
vector
express
one
protein
express
via
dual
ht
vector
togeth
anoth
vector
express
detun
use
nonhtcontain
utr
result
downregul
format
clp
signific
shift
equilibrium
toward
vlp
format
total
protein
yield
use
vector
mg
per
kg
biomass
final
yield
gradientpurifi
vlp
mg
per
kggratifyingli
high
given
vaccin
dose
see
vlpsdose
test
plantmad
antigen
done
sheep
immunogen
assess
inject
two
sheep
vlp
mix
vv
freund
incomplet
adjuv
boost
day
serum
collect
day
first
boost
posit
btv
antibodi
use
commerci
elisa
test
kit
serum
day
final
bleed
react
four
structur
protein
western
blot
strongest
reactiv
toward
major
immunogen
determin
abund
structur
protein
efficaci
test
inject
four
group
five
sheep
either
vlp
clp
mix
vv
montanid
vg
adjuv
tcid
ml
commerci
live
attenu
boost
day
anim
challeng
ml
infect
sheep
blood
contain
live
day
clinic
reaction
monitor
week
plantproduc
vlp
ident
protect
efficaci
profil
assess
clinic
reaction
index
cri
live
attenu
vaccin
plantproduc
clp
poorli
protect
sera
vlp
live
attenu
vaccin
group
show
high
serum
neutral
titr
day
howev
vlp
induc
high
antibodi
level
booster
inject
wherea
neutralis
antibodi
elicit
attenu
vaccin
soon
day
vaccin
plantproduc
clp
offer
partial
protect
live
viru
challeng
similar
insect
cellproduc
clp
result
investig
signific
biofarm
vaccinolog
particular
number
reason
first
gener
find
show
possibl
reason
easili
produc
multiprotein
complex
vari
stoichiometri
approach
could
also
appli
complex
virus
relat
african
horsesick
viru
human
rotaviru
picornavirus
polioviru
foot
mouth
diseas
viru
second
btv
particular
abil
produc
high
level
properlyassembl
vlp
protect
sheep
valuabl
proof
concept
efficaci
vaccin
import
emerg
diseas
addit
timescal
mere
day
product
follow
prepar
agroinfiltr
inoculum
mean
possibl
respond
quickli
potenti
local
outbreak
emerg
diseas
one
health
initi
http
wwwonehealthin
com
strategi
expand
interdisciplinari
collabor
commun
aspect
health
care
human
anim
environ
hope
achiev
inter
alia
joint
effort
develop
evalu
new
diagnost
method
medicin
vaccin
prevent
control
diseas
across
speci
number
obviou
viral
vaccin
target
initi
zoonot
virus
affect
domest
farm
livestock
either
unsatisfactori
human
vaccin
therapeut
human
vaccin
highimpact
recent
emerg
virus
vaccin
anim
human
good
exampl
former
categori
would
rabi
viru
exampl
second
would
agent
sever
acut
respiratori
syndrom
sar
middl
eastern
respiratori
syndrom
mer
coronavirus
cov
west
nile
viru
wnv
ebola
marburg
filovirus
thoma
monath
also
recent
defin
one
health
paradigm
specifi
three
framework
develop
use
vaccin
control
zoonos
given
obvious
target
surpris
explor
potenti
plantmad
vaccin
rabi
one
rel
earli
chimaera
alfalfa
mosaic
viru
cp
epitop
deriv
glycoprotein
g
nucleoprotein
success
express
plant
via
two
differ
plant
virusbas
system
parenterallyinject
extract
protect
mice
challeng
human
volunt
ingest
rcpcontain
plant
materi
produc
rabi
virusneutralis
antibodi
fulllength
synthet
g
protein
genewith
plant
secret
signal
peptid
er
retent
signalwa
found
express
reason
well
tsp
transgen
tobacco
purifi
protein
elicit
complet
protect
virul
intracerebr
challeng
intraperitoneallyimmunis
mice
develop
effect
oral
vaccin
rabi
also
report
singl
dose
vnukovo
strain
rabi
glycoprotein
g
transgen
maiz
seed
contain
antigen
tsp
protect
vaccin
mice
lethal
vampir
bat
rabi
viru
challeng
test
vaccin
done
sheep
maiz
kernel
contain
differ
dose
g
protein
mg
given
singl
dose
oral
rout
mg
dose
elicit
degre
protect
compar
confer
inject
commerci
vaccin
author
state
first
studi
oral
administ
edibl
vaccin
show
efficaci
polygastr
model
import
landmark
veterinari
potenti
one
health
vaccinolog
two
import
diseas
agent
prime
candid
consider
one
health
vaccin
occur
almost
exclus
develop
countri
tickborn
crimeancongo
haemorrhag
fever
viru
cchfv
mosquitoborn
rift
valley
fever
viru
rvfv
famili
bunyavirus
cchfv
wider
distribut
includ
africa
asia
southern
eastern
europ
middl
east
rvfv
larg
restrict
subsaharan
africa
howev
virus
regard
emerg
potenti
rvfv
particular
regard
potenti
spread
europ
asia
america
attenu
live
vaccin
avail
rvfv
regard
signific
side
effect
accept
vaccin
either
viru
gener
use
human
recent
studi
investig
express
two
neutral
epitoperich
cchfv
envelop
glycoprotein
gc
gn
hairi
root
cultur
leav
deriv
transgen
tobacco
plant
protein
accumul
level
mgkg
biomass
hairi
root
mgkg
leav
separ
group
mice
fed
transgen
leav
root
fed
plant
materi
inject
sc
plantmad
protein
vaccin
attenu
cchfv
vaccin
posit
control
mice
immunis
group
consist
rise
antigc
gn
igg
iga
antibodi
serum
faec
respect
mice
group
fed
parenter
boost
howev
exhibit
signific
rise
anticchfv
igg
titr
compar
oralonli
singl
boost
addit
plantpurifi
gc
gn
protein
react
human
immunoglobulin
serum
patient
recov
cchfv
infect
potenti
recombin
protein
product
plant
cchfv
vaccin
appear
obviou
although
yield
seem
low
routin
product
product
rift
valley
fever
viru
antigen
plant
much
less
well
studi
one
phd
thesi
report
express
truncat
gn
solubl
ectodomain
construct
nucleoprotein
n
gene
transgen
arabidopsi
thaliana
studi
chose
two
antigen
gn
effect
elicit
neutralis
antibodi
two
envelop
glycoprotein
recombin
gn
ectodomain
tgn
known
protect
n
antigen
elicit
nonneutralis
antibodi
also
strong
cellular
immun
respons
partial
protect
n
protein
accumul
high
level
truncat
gn
protein
accumul
level
detect
western
blot
feed
group
mice
transgen
plant
materi
three
time
week
contain
tgn
n
protein
per
mice
result
seroconvers
second
feed
antigen
higher
titr
n
compar
tgn
result
preliminari
far
vaccin
goe
indic
feasibl
first
use
transgen
transientlyproduc
antigen
plant
tissu
oral
vaccin
anim
second
produc
antigen
complet
partial
purif
process
could
result
human
vaccin
use
recent
review
detail
plantbas
antibodi
product
may
lower
upfront
cost
shorter
time
clinic
market
suppli
lower
cost
good
cog
improv
pharmacokinet
safeti
efficaci
object
exampl
import
aspect
rabi
diseas
prevent
therapi
given
mani
peopl
develop
countri
get
bitten
suspect
rabid
anim
annuallyand
major
develop
area
product
potent
rabiesneutralis
antibodi
plant
given
prevail
situat
mainli
equineproduc
sera
short
suppli
variabl
qualiti
consortium
research
includ
south
african
recent
describ
engin
product
transgen
n
tabacum
plant
humanis
igg
version
broadli
neutralis
murin
mab
murin
version
purif
via
agaros
protein
ag
affin
chromatographi
yield
mgkg
biomass
tsp
chimaer
mab
mgkg
biomass
tsp
murin
ab
antibodi
assembl
properli
equival
hybridomaproduc
mab
neutralis
panel
lyssavirus
includ
phylogroup
virus
classic
rabv
duvenhag
viru
european
bat
lyssaviru
type
australian
bat
lyssaviru
although
neutralis
seen
phylogroup
ii
virus
lago
bat
viru
mokola
viru
efficaci
postexposur
prophylaxi
humanis
ab
test
hamster
inject
lethal
dose
strain
viru
plantproduc
antibodi
appar
effect
commerci
human
rabi
immunoglobulin
hrig
rabigam
surviv
treatment
group
day
zero
hrig
plant
ab
group
respect
day
product
antiebola
viru
antibodi
also
recent
explor
plant
could
yet
becom
import
part
arsen
prevent
diseas
healthcar
worker
given
time
write
uncontrol
ebola
haemorrhag
fever
outbreak
still
rage
west
africa
http
wwwwhointcsrdonarch
diseaseebolaen
spread
guinea
sierra
leon
liberia
nigeria
spain
usa
http
wwwpromedmailorgdirectphp
use
experiment
solut
suggest
put
practic
background
use
highyield
geminivirusbas
transient
express
system
n
benthamiana
particularli
suit
simultan
express
sever
protein
previous
allow
express
mab
known
protect
anim
ebola
viru
infect
level
gkg
biomass
group
also
use
vector
system
describ
detail
lettuc
produc
potenti
therapeut
mab
ebola
west
nile
virus
comprehens
investig
report
recent
plant
product
mab
postexposur
prophylaxi
ebola
viru
infect
rhesu
macaqu
three
ebolaspecif
mousehuman
chimaer
mab
latter
two
neutralis
produc
whole
n
benthamiana
plant
via
agroinfilr
magnicon
tmvderiv
viral
vector
mixtur
three
mabscal
singl
dose
mgkg
per
mab
hour
postinfect
follow
dose
day
protect
macaqu
lethal
challeng
pfu
ebola
viru
research
subsequ
show
signific
protect
treatment
given
hour
postinfect
four
six
monkey
test
surviv
compar
none
two
control
surviv
anim
treat
experienc
insignific
viraemia
neglig
clinic
symptom
compar
control
anim
signific
find
plantproduc
mab
three
time
potent
cho
cellproduc
equivalentsa
clear
case
plant
product
lead
biobett
followup
work
investig
efficaci
treatment
confirm
infect
rhesu
macaqu
accord
diagnost
protocol
us
food
drug
administr
emerg
use
author
experi
treat
anim
surviv
wherea
control
test
previous
challeng
protocol
die
infect
articl
publish
ebola
outbreak
detail
therapeut
use
rhesu
macaqu
cocktail
antiebola
mab
call
zmapp
describ
successor
incorpor
compon
zmab
cocktail
develop
nation
microbiolog
laboratori
public
health
agenc
canada
anoth
antibodi
mixtur
develop
mapp
biopharmaceut
san
diego
defyru
toronto
manufactur
kentucki
bioprocess
cocktail
prove
abl
rescu
macaqu
administ
day
post
live
viru
challeng
noteworthi
advanc
diseas
mani
anim
indic
elev
liver
enzym
mucos
haemorrhag
generalis
petechia
revers
lead
full
recoveri
zmapp
also
found
bind
virion
guinean
variant
ebola
implic
present
outbreak
author
claim
zmapp
exce
efficaci
therapeut
describ
far
result
warrant
develop
cocktail
clinic
use
news
receiv
consider
articl
may
vindic
view
report
quot
come
nation
institut
allergi
infecti
diseas
state
two
us
healthcar
worker
contract
ebola
liberia
treat
zmapp
despit
given
nine
day
postinfect
one
case
appear
effect
later
develop
therapi
also
given
anoth
five
peopl
two
die
us
govern
negoti
time
write
produc
larg
amount
zmapp
firstlin
therapi
illustr
scaleup
problem
face
manufactur
macaqu
trial
refer
anim
given
three
dose
zmapp
mgkg
intraven
interv
adult
kg
human
given
dose
would
mean
total
gram
zmapp
assum
optim
purifi
yield
three
mab
individu
mgkg
plant
biomass
would
mean
kg
n
benthamiana
would
need
dose
one
person
optim
biofarm
may
scalabl
technolog
produc
mab
therapeut
sort
scale
requir
resourc
far
larger
current
exist
novel
applic
technolog
also
use
produc
ebola
immun
complex
eic
n
benthamiana
consist
ebola
envelop
glycoprotein
fuse
cterminu
heavi
chain
humanis
mab
bind
linear
epitop
geminiviru
vectormedi
coexpress
fusion
light
chain
produc
assembl
immunoglobulin
purifi
protein
g
affin
chromatographi
result
molecul
bound
complement
factor
indic
immun
complex
format
subcutan
immunis
mice
purifi
eic
elicit
high
level
antibodi
product
compar
use
vlp
first
publish
account
ebola
viru
candid
vaccin
produc
plant
prospect
increas
use
plant
manufactur
pharmaceut
gener
look
increasingli
bright
especi
recent
approv
licensur
protalix
carrot
cellproduc
gaucher
diseas
therapeut
enzym
glucocerebrosidas
trade
taligluceras
alfa
http
wwwprotalixcom
productselelysotaliglucerasealfaasp
product
approv
us
food
drug
administr
inject
may
longterm
replac
therapi
adult
confirm
diagnosi
type
gaucher
diseas
market
biosimilar
mammalian
cellproduc
enzym
fact
biobett
given
natur
mannosylatedwhich
aid
uptak
macrophag
exampleunlik
convent
product
chemic
alter
biolog
therapeut
mab
use
antihiv
agent
microbicid
also
get
close
registrationand
recent
experi
antiebola
mab
may
well
speed
process
howev
prospect
anim
vaccin
gener
possibl
human
therapeut
vaccin
also
seem
favour
given
increas
number
proof
efficaci
sphere
prophylact
human
vaccin
specif
brightin
short
term
least
length
rigour
human
prophylact
vaccin
development
clinic
test
path
compar
anim
human
therapeut
vaccin
huge
obstacl
commerci
product
novel
biofarm
vaccin
entrench
invest
convent
technolog
big
pharma
may
technolog
find
nich
fring
convent
vaccinolog
need
smallscal
product
vaccin
orphan
diseas
rapid
respons
bioterrorrel
emerg
viral
diseas
outbreak
one
area
biofarm
vaccin
could
break
soon
could
rapidrespons
vaccin
novel
influenza
viru
outbreak
capac
respons
alreadi
demonstr
see
remain
put
test
reallif
scenario
happen
increas
likelihood
technolog
employ
agent
merscov
rvfv
west
nile
chikungunya
virus
one
health
principl
import
widespread
applic
biofarmingor
properli
plant
molecular
farmingthat
anticip
long
come
still
cynic
doubt
ever
happen
howev
almost
certainli
case
enough
accumul
evid
proof
principl
human
anim
efficaci
mainli
anim
human
great
potenti
cheaper
rapid
wide
scalabl
manufactur
highvalu
biolog
pharmaceut
longer
reason
deni
case
viral
vaccin
therapeut
specif
prove
possibl
routin
make
fullyassembl
complex
vlp
immunoglobulin
either
elicit
potent
protect
immun
respons
diseasereduc
therapeut
effect
shown
anim
model
recent
histori
plantmad
hbv
hpv
hiv
vaccin
candid
particular
shown
huge
yield
increas
viral
antigen
product
larg
result
applic
sophist
transient
express
techniqu
rapidli
becom
industri
norm
surpris
revel
easi
make
highyield
haonli
vlp
influenza
virus
plant
could
transform
particular
industri
fact
plantmad
btv
vlp
probabl
effect
insector
mammalian
cellmad
vlp
probabl
far
cheaper
make
far
safer
make
use
attenu
btv
vaccin
thu
seem
reason
safe
predict
biofarm
viral
vaccin
approv
wide
least
anim
use
near
futur
possibl
also
use
therapi
exist
infect
emerg
respons
therapeut
vaccin
human
slightli
longer
termsuch
rabi
possibl
ebola
hope
approv
prophylact
vaccin
humanssuch
season
influenzawil
follow
slightli
longer
term
research
group
previous
receiv
fund
era
biotech
barcelona
spain
present
medicago
inc
quebec
citi
canada
funder
role
prepar
manuscript
author
inform
epr
conceiv
wrote
edit
commun
review
